Atrophic cardiomyocyte signaling in hypertensive heart disease

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 6, 2013, Pages 497-506

  Kamalov, German ^a,b   Zhao, Wenyuan ^a   Zhao, Tieqiang ^a   Sun, Yao ^a   Ahokas, Robert A ^a   Marion, Tony N ^a   Al Darazi, Fahed ^a   Gerling, Ivan C ^a   Bhattacharya, Syamal K ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Aldosteronism; Atrophy; Cardiomyocytes; ER stress; Hypertrophy; Oxidative stress

Indexed keywords

8 ISOPROSTANE; ALDOSTERONE; ATROGIN 1; BINDING PROTEIN; MESSENGER RNA; METALLOTHIONEIN; MUSCLE RING FINGER 1 PROTEIN; MYOSIN HEAVY CHAIN BETA; SODIUM CHLORIDE; UBIQUITIN PROTEIN LIGASE; X BOX BINDING PROTEIN 1;

AGE DISTRIBUTION; ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELEVATED BLOOD PRESSURE; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HEART DISEASE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HEART VENTRICLE FUNCTION; HYPERTENSIVE HEART DISEASE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; RAT; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; CARDIOTONIC AGENTS; CELL SIZE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM STRESS; HEART VENTRICLES; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MUSCLE PROTEINS; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION;

EID: 84890548723     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000011     Document Type: Article

References (69)

1. Weber KT. Enhanced cardiovascular risk in hypertensive heart disease. Cardiovasc Risk Factors. 1995;5: 87-92.
2. Diez J, Lopez B, Gonzalez A, et al. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol. 2001;16: 328-335.
3. Sugihara N, Genda A, Shimizu M, et al. Diastolic dysfunction and its relation to myocardial fibrosis in essential hypertension [in Japanese]. J Cardiol. 1988;18: 353-361.
4. Sugihara N, Genda A, Shimizu M, et al. Quantitation of myocardial fibrosis and its relation to function in essential hypertension and hypertrophic cardiomyopathy. Clin Cardiol. 1988;11: 771-778.
5. Shapiro LM, McKenna WJ. Left ventricular hypertrophy: relation of structure to diastolic function in hypertension. Br Heart J. 1984;51: 637-642.
6. Cotran RS, Kumar V, Robbins SL. The heart. In: Cotran RS, Kumar V, Robbins SL, eds. Robbins Pathologic Basis of Disease. 4th ed. Philadelphia, PA: W B Saunders; 1989: 597-656.
7. Karsner HT. Human Pathology. Philadelphia, PA: JB Lippincott; 1955.
8. Pearlman ES, Weber KT, Janicki JS, et al. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 1982;46: 158-164.
9. Huysman JAN, Vliegen HW, Van der Laarse A, et al. Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol Res Pract. 1989;184: 577-581.
10. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 1998;16: 1031-1041.
11. Díez J, Laviades C, Mayor G, et al. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation. 1995;91: 1450-1456.
12. Swynghedauw B. Molecular mechanisms of myocardial remodelling. Physiol Rev. 1999;79: 215-262.
13. Schwartz K, Boheler KR, de la Bastie D, et al. Switches in cardiac muscle gene expression as a result of pressure and volume overload. Am J Physiol. 1992;262:R364-R369.
14. Pandya K, Kim HS, Smithies O. Fibrosis, not cell size, delineates b-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo. Proc Natl Acad Sci U S A. 2006;103: 16864-16869.
15. López JE, Myagmar BE, Swigart PM, et al. b-myosin heavy chain is induced by pressure overload in a minor subpopulation of smaller mouse cardiac myocytes. Circ Res. 2011;109: 629-638.
16. Nishikawa T, Kasajima T, Naruse M, et al. Immunohistochemical study on human atrial natriuretic polypeptide in the ventricle of hearts with endocardial fibroelastosis. Am J Cardiovasc Pathol. 1990;3: 247-251.
17. Saito Y, Nakao K, Arai H, et al. Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest. 1989;83: 298-305.
18. Takemura G, Fujiwara H, Horike K, et al. Ventricular expression of atrial natriuretic polypeptide and its relations with hemodynamics and histology in dilated human hearts. Circulation. 1989;80: 1137-1147.
19. Takemura G, Fujiwara H, Yoshida H, et al. Identification and distribution of atrial natriuretic polypeptide in ventricular myocardium of humans with myocardial infarction. J Pathol. 1990;161: 285-292.
20. Takemura G, Fujiwara H, Mukoyama M, et al. Expression and distribution of atrial natriuretic peptide in human hypertrophic ventricle of hypertensive hearts and hearts with hypertrophic cardiomyopathy. Circulation. 1991;83: 181-190.
21. Di Nardo P, Minieri M, Carbone A, et al. Myocardial expression of atrial natriuretic factor gene in early stages of hamster cardiomyopathy. Mol Cell Biochem. 1993;125: 179-192.
22. Vikstrom KL, Bohlmeyer T, Factor SM, et al. Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circ Res. 1998;82: 773-778.
23. Razeghi P, Baskin KK, Sharma S, et al. Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart. Biochem Biophys Res Commun. 2006;342: 361-364.
24. Wohlschlaeger J, Sixt SU, Stoeppler T, et al. Ventricular unloading is associated with increased 20s proteasome protein expression in the myocardium. J Heart Lung Transplant. 2010;29: 125-132.
25. Hardziyenka M, Campian ME, Reesink HJ, et al. Right ventricular failure following chronic pressure overload is associated with reduction in left ventricular mass evidence for atrophic remodeling. J Am Coll Cardiol. 2011;57: 921-928.
26. Gruber C, Nink N, Nikam S, et al. Myocardial remodelling in left ventricular atrophy induced by caloric restriction. J Anat. 2012;220: 179-185.
27. Pansani MC, Azevedo PS, Rafacho BP, et al. Atrophic cardiac remodeling induced by taurine deficiency in Wistar rats. PLoS One. 2012;7: e41439.
28. Willis MS, Rojas M, Li L, et al. Muscle ring finger 1 mediates cardiac atrophy in vivo. Am J Physiol Heart Circ Physiol. 2009;296:H997-H1006.
29. Zaglia T, Milan G, Franzoso M, et al. Cardiac sympathetic neurons provide trophic signal to the heart via b2-adrenoceptor-dependent regulation of proteolysis. Cardiovasc Res. 2013;97: 240-250.
30. Novaes RD, Penitente AR, Gonçalves RV, et al. Trypanosoma cruzi infection induces morphological reorganization of the myocardium parenchyma and stroma, and modifies the mechanical properties of atrial and ventricular cardiomyocytes in rats. Cardiovasc Pathol. 2013;22: 270-279.
31. Hunter RB, Mitchell-Felton H, Essig DA, et al. Expression of endoplasmic reticulum stress proteins during skeletal muscle disuse atrophy. Am J Physiol Cell Physiol. 2001;281:C1285-C1290.
32. Kim HJ, Jamart C, Deldicque L, et al. Endoplasmic reticulum stress markers and ubiquitin-proteasome pathway activity in response to a 200-km run. Med Sci Sports Exerc. 2011;43: 18-25.
33. Min K, Smuder AJ, Kwon OS, et al. Mitochondrial-targeted antioxidants protect skeletal muscle against immobilization-induced muscle atrophy. J Appl Physiol (1985). 2011;111: 1459-1466.
34. Pellegrino MA, Desaphy JF, Brocca L, et al. Redox homeostasis, oxidative stress and disuse muscle atrophy. J Physiol. 2011;589: 2147-2160.
35. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol. 2004;122: 339-352.
36. Ferdous A, Battiprolu PK, Ni YG, et al. FoxO, autophagy, and cardiac remodeling. J Cardiovasc Transl Res. 2010;3: 355-364.
37. Schips TG, Wietelmann A, Höhn K, et al. FoxO3 induces reversible cardiac atrophy and autophagy in a transgenic mouse model. Cardiovasc Res. 2011;91: 587-597.
38. Brilla CG, Pick R, Tan LB, et al. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res. 1990;67: 1355-1364.
39. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol. 2002;161: 1773-1781.
40. Campbell SE, Diaz-Arias AA, Weber KT. Fibrosis of the human heart and systemic organs in adrenal adenoma. Blood Press. 1992;1: 149-156.
41. Wang J, Song Y, Elsherif L, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation. 2006;113: 544-554.
42. Gandhi MS, Deshmukh PA, Kamalov G, et al. Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism. J Cardiovasc Pharmacol. 2008;52: 245-252.
43. Kamalov G, Ahokas RA, Zhao W, et al. Uncoupling the coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria seen in aldosteronism. J Cardiovasc Pharmacol. 2010;55: 248-254.
44. Thomas M, Vidal A, Bhattacharya SK, et al. Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone. Am J Physiol Heart Circ Physiol. 2007;293:H2361-H2366.
45. Chhokar VS, Sun Y, Bhattacharya SK, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111: 871-878.
46. Kamalov G, Deshmukh PA, Baburyan NY, et al. Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism. J Cardiovasc Pharmacol. 2009;53: 414-423.
47. Thuerauf DJ, Marcinko M, Gude N, et al. Activation of the unfolded protein response in infarcted mouse heart and hypoxic cultured cardiac myocytes. Circ Res. 2006;99: 275-282.
48. Iwakoshi NN, Lee AH, Vallabhajosyula P, et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol. 2003;4: 321-329.
49. Weber KT, Janicki JS. Instantaneous force-velocity-length relations in isolated dog heart. Am J Physiol. 1977;232:H241-H249.
50. Campbell SE, Korecky B, Rakusan K. Remodeling of myocyte dimensions in hypertrophic and atrophic rat hearts. Circ Res. 1991;68: 984-996.
51. Jalil JE, Janicki JS, Pick R, et al. Fibrosis-induced reduction of endomyocardium in the rat after isoproterenol treatment. Circ Res. 1989;65: 258-264.
52. Savinova OV, Gerdes AM. Myocyte changes in heart failure. Heart Fail Clin. 2012;8: 1-6.
53. Chhokar VS, Sun Y, Bhattacharya SK, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol. 2004;287:H2023-H2026.
54. Shahbaz AU, Kamalov G, Zhao W, et al. Mitochondria-targeted cardioprotection in aldosteronism. J Cardiovasc Pharmacol. 2011;57: 37-43.
55. Cheema Y, Sherrod JN, Shahbaz AU, et al. Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol. J Cardiovasc Pharmacol. 2011;58: 80-86.
56. Khan MU, Cheema Y, Shahbaz AU, et al. Mitochondria play a central role in nonischemic cardiomyocyte necrosis: common to acute and chronic stressor states. Pflugers Arch. 2012;464: 123-131.
57. Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes the proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol. 2003;285:H813-H821.
58. Ahokas RA, Warrington KJ, Gerling IC, et al. Aldosteronism and peripheral blood mononuclear cell activation. A neuroendocrine-immune interface. Circ Res. 2003;93:e124-e135.
59. Sun Y, Zhang J, Zhang JQ, et al. Local angiotensin II and transforming growth factor-b1 in renal fibrosis of rats. Hypertension. 2000;35: 1078-1084.
60. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57: 132-140.
61. Chilton L, Giles WR, Smith GL. Evidence of intercellular coupling between co-cultured adult rabbit ventricular myocytes and myofibroblasts. J Physiol. 2007;583: 225-236.
62. Rohr S. Myofibroblasts in diseased hearts: new players in cardiac arrhythmias? Heart Rhythm. 2009;6: 848-856.
63. Vasquez C, Mohandas P, Louie KL, et al. Enhanced fibroblastmyocyte interactions in response to cardiac injury. Circ Res. 2010;107: 1011-1020.
64. Sun Y, Weber KT. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res. 1994;28: 1623-1628.
65. Katwa LC, Campbell SE, Tyagi SC, et al. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol. 1997;29: 1375-1386.
66. Razeghi P, Sharma S, Ying J, et al. Atrophic remodeling of the heart in vivo simultaneously activates pathways of protein synthesis and degradation. Circulation. 2003;108: 2536-2541.
67. Ahokas RA, Sun Y, Bhattacharya SK, et al. Aldosteronism and a proinflammatory vascular phenotype. Role of Mg2+, Ca2+ and H2O2 in peripheral blood mononuclear cells. Circulation. 2005;111: 51-57.
68. Gladden JD, Zelickson BR, Wei CC, et al. Novel insights into interactions between mitochondria and xanthine oxidase in acute cardiac volume overload. Free Radic Biol Med. 2011;51: 1975-1984.
69. Berry JM, Le V, Rotter D, et al. Reversibility of adverse, calcineurindependent cardiac remodeling. Circ Res. 2011;109: 407-417.